231 related articles for article (PubMed ID: 28762388)
41. Cytoreductive nephrectomy in metastatic renal cell carcinoma: the evolving role of surgery in the era of molecular targeted therapy.
Kwan KG; Kapoor A
Curr Opin Support Palliat Care; 2009 Sep; 3(3):157-65. PubMed ID: 19528804
[TBL] [Abstract][Full Text] [Related]
42. The Evolution of Nephrectomy and Patient Characteristics in Metastatic Renal Cell Carcinoma Patients Enrolled Into First-Line Tyrosine Kinase Inhibitors Clinical Trials.
Sella A; Wang K; Sella T
Clin Genitourin Cancer; 2016 Oct; 14(5):415-419. PubMed ID: 27105724
[TBL] [Abstract][Full Text] [Related]
43. [Problems in the therapy of kidney neoplasms].
Masuda F
Nihon Hinyokika Gakkai Zasshi; 1985 Nov; 76(11):1612-8. PubMed ID: 3835352
[No Abstract] [Full Text] [Related]
44. [Are immunotherapy and chemotherapy in metastatic renal cell cancer out?].
Schmitz-Dräger BJ
Urologe A; 1992 Jul; 31(4):213-4. PubMed ID: 1514204
[No Abstract] [Full Text] [Related]
45. Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer.
Soria F; Beleni AI; D'Andrea D; Resch I; Gust KM; Gontero P; Shariat SF
World J Urol; 2018 Nov; 36(11):1703-1709. PubMed ID: 29549485
[TBL] [Abstract][Full Text] [Related]
46. Renal parenchymal carcinoma in children.
Booth CM
Br J Surg; 1986 Apr; 73(4):313-7. PubMed ID: 3697666
[TBL] [Abstract][Full Text] [Related]
47. Clinically nonmetastatic renal cell carcinoma with sarcomatoid dedifferentiation: Natural history and outcomes after surgical resection with curative intent.
Merrill MM; Wood CG; Tannir NM; Slack RS; Babaian KN; Jonasch E; Pagliaro LC; Compton Z; Tamboli P; Sircar K; Pisters LL; Matin SF; Karam JA
Urol Oncol; 2015 Apr; 33(4):166.e21-9. PubMed ID: 25700975
[TBL] [Abstract][Full Text] [Related]
48. [Immunotherapy of renal cell carcinoma: results from current phase-III-trials].
Doehn C; Jocham D
Aktuelle Urol; 2004 Apr; 35(2):121-9. PubMed ID: 15146376
[TBL] [Abstract][Full Text] [Related]
49. Comparative Survival following Initial Cytoreductive Nephrectomy versus Initial Targeted Therapy for Metastatic Renal Cell Carcinoma.
Bhindi B; Habermann EB; Mason RJ; Costello BA; Pagliaro LC; Thompson RH; Leibovich BC; Boorjian SA
J Urol; 2018 Sep; 200(3):528-534. PubMed ID: 29574109
[TBL] [Abstract][Full Text] [Related]
50. Nephrectomy for metastatic renal-cell cancer.
Copur MS; Ledakis P; Norvell M
N Engl J Med; 2002 Apr; 346(14):1095-6. PubMed ID: 11936126
[No Abstract] [Full Text] [Related]
51. Adjuvant therapy for high-risk renal cell carcinoma after nephrectomy how many trials are positive? Only one or more than one.
Ravaud A
Asia Pac J Clin Oncol; 2020 Sep; 16 Suppl 3():12-17. PubMed ID: 32852898
[TBL] [Abstract][Full Text] [Related]
52. Therapeutic options in renal cell carcinoma.
Buzaid AC; Todd MB
Semin Oncol; 1989 Feb; 16(1 Suppl 1):12-9. PubMed ID: 2465574
[TBL] [Abstract][Full Text] [Related]
53. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.
Motzer RJ; Mazumdar M; Bacik J; Berg W; Amsterdam A; Ferrara J
J Clin Oncol; 1999 Aug; 17(8):2530-40. PubMed ID: 10561319
[TBL] [Abstract][Full Text] [Related]
54. Outcomes of Patients with Renal Cell Carcinoma and Sarcomatoid Dedifferentiation Treated with Nephrectomy and Systemic Therapies: Comparison between the Cytokine and Targeted Therapy Eras.
Keskin SK; Msaouel P; Hess KR; Yu KJ; Matin SF; Sircar K; Tamboli P; Jonasch E; Wood CG; Karam JA; Tannir NM
J Urol; 2017 Sep; 198(3):530-537. PubMed ID: 28411072
[TBL] [Abstract][Full Text] [Related]
55. Prognostic factors in renal cell cancer.
Park WH; Eisen T
BJU Int; 2007 May; 99(5 Pt B):1277-81. PubMed ID: 17441924
[No Abstract] [Full Text] [Related]
56. Integrating Immunotherapy Into the Management of Renal Cell Carcinoma.
Zibelman M; Plimack ER
J Natl Compr Canc Netw; 2017 Jun; 15(6):841-847. PubMed ID: 28596263
[TBL] [Abstract][Full Text] [Related]
57. Expanding the indications for surgery and adjuvant interleukin-2-based immunotherapy in patients with advanced renal cell carcinoma.
Belldegrun A; Shvarts O; Figlin RA
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S88-92. PubMed ID: 10685666
[TBL] [Abstract][Full Text] [Related]
58. [A clinical study of renal cell carcinoma].
Uchida T; Izumi H; Kobayashi K; Arakawa T; Honda N; Omata T; Odajima K; Mashimo S; Endo T; Ishibashi A
Hinyokika Kiyo; 1985 Nov; 31(11):1919-25. PubMed ID: 4091134
[TBL] [Abstract][Full Text] [Related]
59. Renal cell carcinoma: urologists in a new era.
Uzzo RG
J Urol; 2005 Nov; 174(5):1723-4. PubMed ID: 16217270
[No Abstract] [Full Text] [Related]
60. Validation of the tumor, nodes and metastasis classification of renal cell carcinoma.
Bassil B; Dosoretz DE; Prout GR
J Urol; 1985 Sep; 134(3):450-4. PubMed ID: 4032539
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
